Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for G8708J109 since 12/18/2024, largest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Biotechnology Value Fund L P
13G
|
5.5% |
8/12/2026
Event 8/5/2026
|
|
| Biotechnology Value Fund L P | 2.9% | ||
| BVF I GP LLC | 2.9% | ||
| Biotechnology Value Fund II LP | 2.1% | ||
| BVF II GP LLC | 2.1% | ||
| Biotechnology Value Trading Fund OS LP | 0.4% | ||
| BVF Partners OS Ltd. | 0.4% | ||
| BVF GP Holdings LLC | 5.0% | ||
| BVF Partners L P/IL | 5.5% | ||
| BVF Inc/IL | 5.5% | ||
| Lampert Mark N | 5.5% | ||
|
RA Capital Management, L.P.
13G
|
5.5% |
8/13/2026
Event 8/6/2026
|
|
| RA Capital Management, L.P. | 5.5% | ||
| Peter Kolchinsky | 5.5% | ||
| Rajeev Shah | 5.5% | ||
| RA Capital Healthcare Fund, L.P. | 5.5% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 1 | 19.4 k | $243 k |